Improvement of the efficacy of TKI treatment or to slowing down the onset of therapeutic resistance emerged notable objectives, and researchers have increasingly explored the administration of first-line combination therapies for advanced EGFR-mutated NSCLC, including combining TKIs and chemotherapeutic or anti-angiogenic drugs [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.